Acuta Capital Partners buys $15.8 Million stake in Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD) : Acuta Capital Partners scooped up 997,339 additional shares in Amicus Therapeutics during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 2,500,000 shares of Amicus Therapeutics which is valued at $15.8 Million.Amicus Therapeutics makes up approximately 9.32% of Acuta Capital Partners’s portfolio.

Other Hedge Funds, Including , Sabby Management boosted its stake in FOLD in the latest quarter, The investment management firm added 33,663 additional shares and now holds a total of 59,324 shares of Amicus Therapeutics which is valued at $376,114. Amicus Therapeutics makes up approx 0.13% of Sabby Management’s portfolio.Manufacturers Life Insurance Company The boosted its stake in FOLD in the latest quarter, The investment management firm added 1,784 additional shares and now holds a total of 244,576 shares of Amicus Therapeutics which is valued at $1.6 Million.Diam Ltd. boosted its stake in FOLD in the latest quarter, The investment management firm added 67,515 additional shares and now holds a total of 589,121 shares of Amicus Therapeutics which is valued at $3.8 Million. Amicus Therapeutics makes up approx 0.06% of Diam Ltd.’s portfolio.State Board Of Administration Of Florida Retirement System boosted its stake in FOLD in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 40,438 shares of Amicus Therapeutics which is valued at $260,421.

Amicus Therapeutics closed down -0.04 points or -0.56% at $7.1 with 14,70,006 shares getting traded on Wednesday. Post opening the session at $7.19, the shares hit an intraday low of $7.03 and an intraday high of $7.25 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Many Wall Street Analysts have commented on Amicus Therapeutics. BofA/Merrill Initiated Amicus Therapeutics on May 18, 2016 to “Buy”, Price Target of the shares are set at $10.Robert W. Baird Initiated Amicus Therapeutics on Apr 14, 2016 to “Neutral”, Price Target of the shares are set at $9.Company shares were Reiterated by Chardan Capital Markets on Apr 12, 2016 to “Buy”, Firm has raised the Price Target to $ 15 from a previous price target of $10 .

Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.

Leave a Reply

Amicus Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amicus Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.